Cargando…

Predictors of cinacalcet discontinuation and reinitiation in hemodialysis patients: results from 7 European countries

BACKGROUND: The putative benefits of cinacalcet therapy for management of secondary hyperparathyroidism (SHPT) are thought to be most manifested when patients are taking it consistently and as prescribed. Real-world descriptions of cinacalcet prescription discontinuation and reinitiation in European...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fuller, Douglas S., Hallett, David, Dluzniewski, Paul J., Fouqueray, Bruno, Jadoul, Michel, Morgenstern, Hal, Port, Friedrich K., Tentori, Francesca, Pisoni, Ronald L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518810/ https://www.ncbi.nlm.nih.gov/pubmed/31088377 http://dx.doi.org/10.1186/s12882-019-1355-5

Ejemplares similares

The effects of discontinuing cinacalcet at the time of kidney transplantation
por: Jadoul, Michel, et al.
Publicado: (2010)

Understanding associations of hemodialysis practices with clinical and patient-reported outcomes: examples from the DOPPS
por: Port, Friedrich K., et al.
Publicado: (2017)

Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes
por: Louie, Karly S., et al.
Publicado: (2019)

Estimating the Fraction of First-Year Hemodialysis Deaths Attributable to Potentially Modifiable Risk Factors: Results from the DOPPS
por: Karaboyas, Angelo, et al.
Publicado: (2020)

Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design
por: Reams, B. Diane, et al.
Publicado: (2015)

Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women
por: Balasubramanian, Akhila, et al.
Publicado: (2013)

Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness
por: Karaboyas, Angelo, et al.
Publicado: (2022)

International and Racial Differences in Mineral and Bone Disorder Markers and Treatments Over the First 5 Years of Hemodialysis in the Dialysis Outcomes and Practice Patterns Study
por: Chan, Kevin, et al.
Publicado: (2019)

Reinitiation and Subsequent Discontinuation of Antiplatelet Treatment in Nonpersistent Older Patients with Peripheral Arterial Disease
por: Wawruch, Martin, et al.
Publicado: (2021)

Effects of cinacalcet treatment on QT interval in hemodialysis patients
por: Temiz, Gökhan, et al.
Publicado: (2016)

World-wide, mortality is a high risk soon after initiation of hemodialysis
por: Robinson, Bruce, et al.
Publicado: (2013)

European hemodialysis patient satisfaction with phosphate binders is associated with serum phosphorus levels: the Dialysis Outcomes and Practice Patterns Study
por: McCullough, Keith, et al.
Publicado: (2021)

Mortality risk in patients on hemodiafiltration versus hemodialysis: a ‘real-world’ comparison from the DOPPS
por: Locatelli, Francesco, et al.
Publicado: (2018)

Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study
por: Karaboyas, Angelo, et al.
Publicado: (2018)

Patterns of metformin monotherapy discontinuation and reinitiation in people with type 2 diabetes mellitus in New Zealand
por: Horsburgh, Simon, et al.
Publicado: (2021)

Hemodialysis reinitiation using a resurrected mummy fistula: a case report
por: Wan, Ziming, et al.
Publicado: (2018)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Alvarado, Luis, et al.
Publicado: (2022)

Phosphorylation of a reinitiation supporting protein, RISP, determines its function in translation reinitiation
por: Mancera-Martínez, Eder, et al.
Publicado: (2021)

Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events Trial
Publicado: (2015)

Putting a cap on reinitiation
por: LeBrasseur, Nicole
Publicado: (2002)

Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
por: Kuczera, Piotr, et al.
Publicado: (2016)

Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial
por: Wheeler, David C., et al.
Publicado: (2014)

Rapid Decrease of Intact Parathyroid Hormone Could Be a Predictor of Better Response to Cinacalcet in Hemodialysis Patients
por: Kim, Jwa-Kyung, et al.
Publicado: (2013)

High rates of death and hospitalization follow bone fracture among hemodialysis patients
por: Tentori, Francesca, et al.
Publicado: (2013)

Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Otsuka, Keiichi, et al.
Publicado: (2018)

Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism
por: Ni, Zhaohui, et al.
Publicado: (2023)

Response to High rates of death and hospitalization follow bone fracture among hemodialysis patients
por: Tentori, Francesca, et al.
Publicado: (2013)

Cinacalcet: the chemical parathyroidectomy?
por: Bellasi, Antonio, et al.
Publicado: (2013)

Combinations of mineral and bone disorder markers and risk of death and hospitalizations in the international Dialysis Outcomes and Practice Patterns Study
por: Fuller, Douglas S, et al.
Publicado: (2019)

Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism
por: Nakayama, Kazunori, et al.
Publicado: (2013)

Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease
por: Nakatani, Shinya, et al.
Publicado: (2021)

Auxin Signaling in Regulation of Plant Translation Reinitiation
por: Schepetilnikov, Mikhail, et al.
Publicado: (2017)

Hemoglobin A(1c) Levels and Mortality in the Diabetic Hemodialysis Population: Findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS)
por: Ramirez, Sylvia Paz B., et al.
Publicado: (2012)

Association between allopurinol and mortality among Japanese hemodialysis patients: results from the DOPPS
por: Tsuruta, Yuki, et al.
Publicado: (2014)

Partial response to cinacalcet treatment in a patient with secondary hyperparathyroidism undergoing hemodialysis: a case report
por: Conzo, Giovanni, et al.
Publicado: (2012)

The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism
por: Susantitaphong, Paweena, et al.
Publicado: (2019)

The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism
por: Ngamkam, Jaruwan, et al.
Publicado: (2021)

A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride
por: Nakamura, Hironori, et al.
Publicado: (2021)

Cinacalcet Treatment of Primary Hyperparathyroidism
por: Rothe, H. M., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_i4s9kakgpid01co5qqqlsbcpuh